A Review Article Impurity Scavengers Roadmap for Platinum Derivative Formulations

Abstract

Platinum derivative formulations have been facing serious impurity issues, which can lead to degradation of the drug product, affecting its safety and efficacy. The current review article aims to highlight the mitigation of impurities in platinum derivative formulations by focusing on product design and development, as well as the regulatory perspective. The factors contributing to impurity issues in platinum derivative formulations include environmental factors, chemical reactivity, thermodynamic instability, ligand exchange, excipient impurities and contaminants, and container closure system. This review article will provide an overview of the key challenges and solutions for mitigating impurities in platinum derivative formulations.

Keywords

Introduction

The development of stable and effective formulations for platinum derivative anticancer drugs is crucial for their safety and efficacy. Platinum derivative formulations are widely used in cancer treatment, and their stability and purity are essential for their therapeutic effectiveness. However, various factors can contribute to impurity issues in platinum derivative formulations, including environmental factors, chemical reactivity, thermodynamic instability, ligand exchange, excipient impurities and contaminants, and container closure system.

Environmental Factors

Environmental factors such as light, heat, and humidity can affect the stability of platinum derivative formulations. Platinum derivatives are light-sensitive and can undergo photolytic reactions that generate impurities. Physicochemical properties of the formulation, such as pH and ionic strength, can also contribute to the instability of platinum derivatives.

Chemical Reactivity

Platinum compounds can undergo oxidation or reduction, leading to the creation of less stable or potentially toxic species. Understanding redox processes is essential for ensuring the safety and efficacy of platinum derivative formulations. Some platinum complexes contain reactive ligands that can undergo hydrolysis or decompose over time in solution, contributing to instability.

Thermodynamic Instability

Some platinum complexes have inherent thermodynamic properties that promote decomposition or transformation into more stable species. Understanding these properties is essential for ensuring the long-term stability of platinum derivative formulations.

Ligand Exchange

Ligand exchange in platinum complexes is a significant process that influences their stability and efficacy. Formulation strategies that include the careful selection of ligands and stabilizing agents are essential for enhancing the efficacy and safety profiles of platinum derivative formulations.

Excipient Impurities and Contaminants

Excipient impurities and contaminants can catalyze degradation reactions or lead to unwanted side reactions, affecting the stability of platinum derivative formulations. The presence of impurities in excipients can arise from various sources, including manufacturing processes, storage conditions, and interactions with other components.

Container Closure System

The container closure system can also contribute to impurity issues in platinum derivative formulations. The presence of headspace oxygen and dissolved oxygen can affect the stability of platinum derivatives, and the selection of suitable containers and capping materials is essential.

Regulatory Perspectives

Regulatory agencies worldwide have set guidelines to ensure the control of impurities in pharmaceutical formulations. The selection of suitable excipients, container closure systems, and manufacturing processes is essential for ensuring the safety and efficacy of platinum derivative formulations.

CONCLUSION

In conclusion, the mitigation of impurities in platinum derivative formulations requires a comprehensive approach that includes understanding environmental factors, chemical reactivity, thermodynamic instability, ligand exchange, excipient impurities and contaminants, and container closure system. Regulatory agencies worldwide have set guidelines to ensure the control of impurities in pharmaceutical formulations, and the selection of suitable excipients, container closure systems, and manufacturing processes is essential for ensuring the safety and efficacy of platinum derivative formulations.

Future Directions

The development of stable and effective formulations for platinum derivative anticancer drugs requires ongoing research and innovation. The use of novel excipients, container closure systems, and manufacturing processes can help mitigate impurity issues in platinum derivative formulations. Additionally, the use of analytical techniques such as Differential Scanning Calorimetry (DSC), Thermogravimetric Analysis (TGA), Spectroscopic Analysis, and X-ray Powder Diffraction (XRPD) can help monitor the stability of platinum derivative formulations.

Recommendations

1. Conduct thorough excipient screening and qualification to ensure their quality and purity. 2. Develop and implement suitable packaging and container closure systems to minimize the impact of environmental factors.

3. Monitor the stability of platinum derivative formulations using analytical techniques such as DSC, TGA, Spectroscopic Analysis, and XRPD.

4. Develop and employ novel excipients, container closure systems, and manufacturing processes to mitigate impurity issues.

5. Continuously review and refine formulation design and development processes to ensure the stability and efficacy of platinum derivative formulations. By following these recommendations and understanding the factors contributing to impurity issues in platinum derivative formulations, pharmaceutical companies can develop stable and effective formulations that ensure the safety and efficacy of platinum derivative anticancer drugs.

REFERENCE

1. Wu, Y., Levons, J., Narang, A. S., Raghavan, K., & Rao, V. M. (2011). Reactive impurities in excipients: profiling, identification and mitigation of drug–excipient incompatibility. Aaps Pharmscitech, 12, 1248-1263.
2. Gabri?, A., Hodnik, Ž., & Pajk, S. (2022). Oxidation of Drugs during Drug Product Development: Problems and Solutions. Pharmaceutics, 14(2), 325. https://doi.org/10.3390/pharmaceutics14020325.
3. Tsvetkova, D.; Ivanova, S. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules 2022, 27, 2466. https://doi.org/10.3390/molecules27082466.
4. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5; 740:364-78. doi: 10.1016/j.ejphar.2014.07.025. Epub 2014 Jul 21. PMID: 25058905; PMCID: PMC4146684.
5. Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016 Jun;77(6):1103-24. doi: 10.1007/s00280-016-2976-z. Epub 2016 Feb 17. PMID: 26886018.
6. Berners-Price, S.J., Appleton, T.G. (2000). The Chemistry of Cisplatin in Aqueous Solution. In: Kelland, L.R., Farrell, N.P. (eds) Platinum-Based Drugs in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-012-4_1.
7. US4915956A - Liquid cisplatin formulations - Google Patents. (1987, December 16). Google.com. https://patents.google.com/patent/US4915956A/en
8. US5959133A - Process for the preparation of platinum compounds - Google Patents. (1997, July 4). Google.com. https://patents.google.com/patent/US5959133A/en
9. Zhang, C., Xu, C., Gao, X., Yao, Q. (2022). Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics, 12(5), 2115-2132. https://doi.org/10.7150/thno.69424. 
10. Martinho N, Santos TCB, Florindo HF, Silva LC. Cisplatin-Membrane Interactions and Their Influence on Platinum Complexes Activity and Toxicity. Front Physiol. 2019 Jan 11; 9:1898. doi: 10.3389/fphys.2018.01898. PMID: 30687116; PMCID: PMC6336831.
11. Sen, T., Sarkar, P., Sutradhar, S., Das, D., & Ghosh, B. N. (2024). A review on platinum (II/IV) complexes of Schiff base ligands and application in biological activity. Inorganic Chemistry Communications, 113438. https://doi.org/10.1016/j.inoche.2024.113.
12. PubChem. (2024). Ready-to-use oxaliplatin solutions - Patent US-2006063833-A1 - PubChem. Nih.gov; PubChem. https://pubchem.ncbi.nlm.nih.gov/patent/US-2006063833-A1
13. International Conference on Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use ICH Harmonised Tripartite Guideline Impurities In New Drug Products Q3B(R2) ICHYear: 2006 URL: https://database.ich.org/sites/default/files/Q3B%28R2%29%20Guideline.pdf
14. NIU Chong, LIU Gui-hua, ZHANG Zhong-hu. Progress on the impurities in Oxaliplatin[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(6): 412-414,436. doi: 10.3969/j.issn.1006-0111.2012.06.004.
15. Wei JIN; Wen-ming JIANG; Qian LIU; Xuan GAO; Ye ZHANG; Dan GUO; Min QIAN; Mei-ting REN; Yong-jian YANG. (2018). Study on the structure of an unknown impurity in carboplatin injection and the relationship with the excipient, Yao Xue Xue Bao; (12): 604-608, 2018.
16. Carboplatin and Impurities. Bocsci.com. https://www.bocsci.com/im-carboplatin-and-impurities-list-525.html (accessed 2024-12-21).
17. EP0642792A1 - Stabilized solutions of platinum (II) antitumor agents - Google Patents. (1994, August 10). Google.com. https://patents.google.com/patent/EP0642792A1/en
18. EP1879568B1 - Stable pharmaceutical compositions of platinum (ii) antitumour agents - Google Patents. (2005, July 5). Google.com. https://patents.google.com/patent/ EP1879568B1/en
19. Kapil D. Excipient Impurities in Pharmaceutical Formulations: Unveiling Their Impact and Control - SynThink. SynThink. https://synthinkchemicals.com/excipient-impurities-pharmaceutical-formulations.
20. Ojha, S., Roy, S. K., Kori, A., & Vinukonda, A. (2021). Formulation Development Studies for Sterile Dosages: A Comprehensive Review. Journal of Drug Delivery and Therapeutics, 11(3), 122-125.
21. CN102949353B - oxaliplatin lyophilized pharmaceutical composition for injection and - Google Patents. (2012, October 30). Google.com. https://patents.google.com/patent/ CN102949353B/en
22. US4310515A - Pharmaceutical compositions of cisplatin - Google Patents. (1979, October). Google.com. https://patents.google.com/patent/US4310515A/en
23. hollandapt; hollandapt. Peroxide vs. Platinum Cured Silicone Tubing - What’s the Difference? - Holland Applied Technologies. Holland Applied Technologies. https://hollandapt.com/peroxide-vs-platinum-cured-silicone-tubing-whats-the-difference/ (accessed 2024-12-21).
24. Gasket Material Selection Guide | Custom Gasket Manufacturing. Custom Gasket Manufacturing LLC. https://www.customgasketmfg.com/gasket-materials/.
25. admin. Complete Guide to PTFE Gasket. Asian Sealing Products Pvt. Ltd. https://asiansealing.in/ptfe-gaskets-guide.
26. EP2006328A1 - Composition for rubber stoppers and rubber stoppers for medical use - Google Patents. (2007, April 5). Google.com. https://patents.google.com/patent /EP2006328A1/en
27. https://www.ema.europa.eu/en/sterilisation-medicinal-product-active-substance-excipient-primary-container-scientific-guideline.
28. Research, C. for D. E. and. Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice.
29. Sign in - Google Accounts. (2024). Google.com. https://patents.google.com/patent/ US20070155833A1/en
30. Rx only PLATINOL ® (cisplatin for injection, USP). (n.d.). https://www.accessdata.fda.gov /drugsatfda_docs/label/2011/018057s080lbl.pdf
31. Karbownik A, Sza?ek E, Urjasz H, G??boka A, Mierzwa E, Grze?kowiak E. The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemporary Oncology/ Wspó?czesna Onkologia. 2012;16(5):435-439. doi:10.5114/.
32. US4915956A - Liquid cisplatin formulations - Google Patents. (1987, December 16). Google.com. https://patents.google.com/patent/US4915956A/en
33. EMA. ICH Topic Q 1 a (R2) Stability Testing of New Drug Substances and Products Step 5 Note for Guidance on Stability Testing: Stability Testing of New Drug Substances and Products; 2003. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf